MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, JAZZ made $1,068,900K in revenue. $293,100K in net income. Net profit margin of 27.42%.

Income Overview

Revenue
$1,068,900K
Net Income
$293,100K
Net Profit Margin
27.42%
EPS
$4.43
Unit: Thousand (K) dollars
Revenue Breakdown
    • Xywav
    • Revenue From Contract With Custo...
    • Rylaze Enrylaze
    • Others
Revenue Breakdown
    • Revenue From Contract With Custo...
    • High Sodium AGOxybate Product Ro...
    • Other Royalty And Contract Reven...
Revenue Breakdown
    • US
    • Europe
    • Other Countries
Revenue Breakdown
    • Product And Services Product Sal...
    • Product And Services Royalties A...

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
1,068,900 1,197,926 1,126,107 1,045,712
Cost of product sales (excluding amortization of acquired developed technologies)
134,100 153,528 128,880 116,268
Selling, general and administrative
352,700 406,212 530,647 358,399
Research and development
196,000 213,909 198,203 189,972
Acquired in-process research and development
-0 42,500 905,362
Intangible asset amortization
172,300 169,742 168,368 162,103
Gain on sale of priority review voucher
122,800 ---
Total operating expenses
732,300 943,391 1,068,598 1,732,104
Income (gain) from operations
336,600 254,535 57,509 -686,392
Interest expense, net
-39,900 -45,406 -48,576 -47,363
Foreign exchange gain (loss)
2,500 -658 102 -1,799
Income (gain) before income tax expense (benefit) and equity in gain of investees
299,200 208,471 9,035 -735,554
Income tax expense (benefit)
6,100 4,963 -242,424 -17,170
Equity in loss of investees
0 -57 -47 -86
Net income (gain)
293,100 203,451 251,412 -718,470
Basic EPS
4.73 3.332 4.14 -11.74
Diluted EPS
4.43 3.383 4.08 -11.74
Basic Average Shares
61,900,000 61,055,000 60,696,000 61,194,000
Diluted Average Shares
66,100,000 60,145,000 61,606,000 61,194,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Xywav$408,200K (18.39%↑ Y/Y)Xyrem$31,200K (-16.22%↓ Y/Y)Rylaze Enrylaze$103,700K (10.05%↑ Y/Y)Zepzelca$101,000K (60.23%↑ Y/Y)Defitelio Defibrotide$47,400K (16.57%↑ Y/Y)Modeyso$41,400K Vyxeos$26,600K (-9.96%↓ Y/Y)Ziihera$13,300K (573.42%↑ Y/Y)Revenue From ContractWith Customer...$249,800K (14.73%↑ Y/Y)Sleep$439,400K Oncology$333,400K Epilepsy$249,800K Other Products$2,700K (-43.54%↓ Y/Y)Product And ServicesProduct Sales Net Of...$1,025,300K (22.14%↑ Y/Y)High SodiumAGOxybate Product Royalty...$36,300K (-25.84%↓ Y/Y)Other Royalty AndContract Revenues$7,300K Total revenues$1,068,900K (19.05%↑ Y/Y)Income (gain) fromoperations$336,600K (702.23%↑ Y/Y)Foreign exchange gain(loss)$2,500K (1273.71%↑ Y/Y)Total operatingexpenses$732,300K (-23.22%↓ Y/Y)Gain on sale ofpriority review voucher$122,800K Income (gain) beforeincome tax expense...$299,200K (372.47%↑ Y/Y)Interest expense, net-$39,900K (25.71%↑ Y/Y)Selling, general andadministrative$352,700K (-31.38%↓ Y/Y)Research and development$196,000K (8.50%↑ Y/Y)Intangible assetamortization$172,300K (11.56%↑ Y/Y)Cost of product sales(excluding amortization of...$134,100K (28.18%↑ Y/Y)Net income (gain)$293,100K (416.72%↑ Y/Y)Income tax expense(benefit)$6,100K (134.25%↑ Y/Y)